MA30886B1 - Modifications cristallines - Google Patents

Modifications cristallines

Info

Publication number
MA30886B1
MA30886B1 MA31867A MA31867A MA30886B1 MA 30886 B1 MA30886 B1 MA 30886B1 MA 31867 A MA31867 A MA 31867A MA 31867 A MA31867 A MA 31867A MA 30886 B1 MA30886 B1 MA 30886B1
Authority
MA
Morocco
Prior art keywords
crystalline modifications
quinazolin
piperazin
indol
dione
Prior art date
Application number
MA31867A
Other languages
English (en)
Inventor
Piotr Karpinski
Stephanie Monnier
Elias Ndzie
Dimitris Papoutsakis
Paul Allen Sutton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30886(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30886B1 publication Critical patent/MA30886B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE NOUVELLE FORME CRISTALLINE DU SEL D'ACÉTATE DE 3-(1H-INDOL-3-YL)-4-[2-(4-MÉTHYL-PIPÉRAZIN-1-YL)-QUINAZOLIN-4-YL]-PYRROLE-2,5-DIONE, QUI PEUT ÊTRE UTILISÉE PAR EXEMPLE POUR UNE TRANSPLANTATION.
MA31867A 2006-10-20 2009-05-13 Modifications cristallines MA30886B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85338406P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
MA30886B1 true MA30886B1 (fr) 2009-11-02

Family

ID=38921707

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31867A MA30886B1 (fr) 2006-10-20 2009-05-13 Modifications cristallines

Country Status (23)

Country Link
US (1) US8865897B2 (fr)
EP (1) EP2102195A1 (fr)
JP (1) JP5302199B2 (fr)
KR (1) KR20090073231A (fr)
CN (2) CN101522664B (fr)
AR (1) AR063491A1 (fr)
AU (1) AU2007309558B2 (fr)
BR (1) BRPI0717461A2 (fr)
CA (1) CA2666965A1 (fr)
CL (1) CL2007003006A1 (fr)
EC (1) ECSP099344A (fr)
IL (1) IL197962A (fr)
MA (1) MA30886B1 (fr)
MX (1) MX2009004048A (fr)
MY (1) MY158026A (fr)
NO (1) NO20091970L (fr)
NZ (1) NZ576241A (fr)
PE (1) PE20081133A1 (fr)
RU (1) RU2481341C2 (fr)
TN (1) TN2009000147A1 (fr)
TW (1) TWI399374B (fr)
WO (1) WO2008051440A1 (fr)
ZA (1) ZA200902048B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679484A1 (fr) * 2007-03-09 2008-09-18 Novartis Ag Sels de 3-(1h-indole-3-yl)-4-[2-(4-methyle-piperazine-i-yl)-quinazoline 4-yl]-pyrrole-2,5-dione
US9017528B2 (en) 2011-04-14 2015-04-28 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9005409B2 (en) 2011-04-14 2015-04-14 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9303329B2 (en) 2013-11-11 2016-04-05 Tel Nexx, Inc. Electrochemical deposition apparatus with remote catholyte fluid management

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332770T3 (es) * 2000-11-07 2010-02-12 Novartis Ag Derivados de indolilmaleimida como inhibidores de la proteina quinasa c.
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
MY148901A (en) 2007-06-18 2013-06-14 Sanofi Aventis Pyrrole derivatives as p2y12 antagonists

Also Published As

Publication number Publication date
RU2481341C2 (ru) 2013-05-10
AR063491A1 (es) 2009-01-28
US20100041884A1 (en) 2010-02-18
TW200829572A (en) 2008-07-16
CL2007003006A1 (es) 2008-05-23
ZA200902048B (en) 2010-01-27
CN103265533A (zh) 2013-08-28
IL197962A0 (en) 2009-12-24
CN101522664B (zh) 2013-06-12
KR20090073231A (ko) 2009-07-02
TWI399374B (zh) 2013-06-21
CA2666965A1 (fr) 2008-05-02
WO2008051440A1 (fr) 2008-05-02
ECSP099344A (es) 2009-06-30
PE20081133A1 (es) 2008-09-16
NO20091970L (no) 2009-05-20
IL197962A (en) 2013-08-29
US8865897B2 (en) 2014-10-21
BRPI0717461A2 (pt) 2013-10-08
MY158026A (en) 2016-08-30
JP5302199B2 (ja) 2013-10-02
AU2007309558B2 (en) 2012-05-24
TN2009000147A1 (en) 2010-10-18
NZ576241A (en) 2012-05-25
RU2009118816A (ru) 2010-11-27
MX2009004048A (es) 2009-04-27
EP2102195A1 (fr) 2009-09-23
AU2007309558A1 (en) 2008-05-02
JP2010506927A (ja) 2010-03-04
CN101522664A (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
EA006445B9 (ru) Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции
ATE355838T1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo (3.1.0)hexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
MA31763B1 (fr) Inhibiteurs de kinase de type polo
WO2009016253A3 (fr) N-acyltryptamines à substitution cyanométhyle
MA31707B1 (fr) Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1
TW200616965A (en) Synthesis of n2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents
WO2007062399A3 (fr) Compose cytotoxique speficique du ras oncogene et ses procedes d’utilisation
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
MA29627B1 (fr) Modifications cristallines de la pyraclostrobine
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
CR9690A (es) 3-acilaminobenzanilidas insecticidas
ATE554087T1 (de) Neue kinaseinhibitoren
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA30886B1 (fr) Modifications cristallines
MA31603B1 (fr) Nouvelle forme cristalline du 3-(difluorométhyle)-1-méthyle-n-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)-1h-pyrazole-4-carboxamide
MA32788B1 (fr) 1-(arylsulfonyl)-4-(piperazine-1-yl)-1h-benzimidazoles servant de ligands de la 5-hydroxytryptamine-6
MA31259B1 (fr) Formes solides d'un inhibiteur des kinases raf
NZ595579A (en) 5-Difluoromethoxy-4-hydroxymethyl-1-methyl-3-trifluoromethyl-pyrazole / (5-(difluoromethoxy)-3-(trifluoromethyl)-1-methyl-1H-pyrazol-4-yl)methanol
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
TW200624119A (en) An oral liquid pharmaceutical composition of leukotriene antagonists
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
GB0425548D0 (en) Radiolabelled ligands
ATE452130T1 (de) 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
UY28856A1 (es) Nuevos imidazoles
NO20031745L (no) Inhibisjon av vekstfaktoravhengigheten til tumorceller